Avedro Inc.
McKesson to pay $2B for PSS World Medical | Wall Street Beat
McKesson (NYSE:MCK) agreed to pay $29 per share for PSS World Medical (NSDQ:PSSI) and its medical supplies business in a deal worth $2.1 billion.
New FDA rules imperil Bioject | Wall Street Beat
Diabetes: Abbott lands FDA win for touch-screen glucose monitor | Regulatory Roundup
Is Medtronic’s spine business headed to the auction block? | Wall Street Beat
The message to Medtronic’s (NYSE:MDT) spine business from chairman and CEO Omar Ishrak was clear today: Shape up or ship out.
During a conference call with analysts to discuss the med-tech titan’s fiscal 3rd-quarter results, Ishrak said he was “not happy” that the division posted a 9% revenue decline and warned that the spine unit must raise its game or face the consequences.
Toshiba lands 510(k) for latest Aquilon CT scanner | Regulatory Roundup
Toshiba’s (TYO:6502) American medical products division won 510(k) clearance from the FDA for the latest iteration in its Aquilon line of CT scanners.
The Aquilon Prime is designed for healthcare facilities that need to perform a wide variety of advanced clinical examinations with reduced radiation exposure, according to a press release.
FDA clears Smith & Nephew’s Pico pocket NPWT device | Regulatory Roundup
Smith & Nephew (NYSE:SNN) won a nod from the FDA for its Pico negative-pressure wound therapy system.
The British orthopedics giant’s wound care division said the FDA cleared the device for use in the home and in hospitals. It’s already on the market in Europe, Canada and Australia, according to a press release.
Avedro lands orphan status for corneal ectasia treatment | Regulatory Roundup
Avedro Inc. won an orphan drug designation for a solution used with its KXL irradiation system to treat corneal ectasia following refractive surgery.
The decision sets the Waltham, Mass.-based company up for 7 years of exclusive rights to the U.S. market if the technology pans out.
The VibeX ophthalmic solution is used with the company’s UVA radiation system for corneal cross-linking to treat corneal ectasia following refractive eye surgeries such as Lasik.
InVivo taps spine expert as science chief | Personnel Moves
InVivo Therapeutics Holdings Corp. (OTC:NVIV) appointed spinal cord injury expert Dr. Edward Wirth as its new chief scientist.
InVivo brings Wirth to the team as its waiting for a green light by the FDA to begin human trials of its biodegradable scaffold for treating spinal cord injury.
The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.
Ballantyne takes CFO post at Avedro | Personnel Moves
Waltham, Mass.-based medical device and pharmaceutical company Avedro appointed industry veteran C. Evan Ballantyne as its new chief financial officer.
Prior to the appointment, Ballantyne was the VP & CFO of biopharmaceutical company Clinical Data Inc., chief financial officer of Beverly, Mass.-based ZymeQuest, and vice president at chief operating officer at the ACNielsen Corporation.
Avedro appoints C. Evan Ballantyne as Chief Financial Officer
WALTHAM, Mass.–(BUSINESS WIRE)–Avedro, Inc., a privately held medical device and pharmaceutical company, today announced C. Evan Ballantyne as Chief Financial Officer. In this position, Mr. Ballantyne will be responsible for the Company’s financial affairs and report to David Muller, PhD, President and Chief Executive Officer. Prior to this role, Mr. Ballantyne served as Executive Vice President, Chief Financial Officer of Clinical Data, Inc., a biopharmaceutical company which was acquired in April 2011 by Forest Laboratories, Inc. for $1.3 billion.